Farmmi vs Immucell
Farmmi and Immucell are similar in size: $28.0m and $27.6m of revenue in their latest fiscal years. Immucell grew faster (4.3% against -56.4%). Immucell kept more of each dollar of sales as profit: a net margin of -3.8% against -189.8%. Farmmi carries less debt relative to equity (1.5% against 33.6%).
| Latest fiscal year | FarmmiFAMI, 2025 | ImmucellICCC, 2025 |
|---|---|---|
| Revenue | $28.0m | $27.6m |
| Revenue growth | -56.4% | 4.3% |
| Net income | −$53.1m | −$1.0m |
| Operating margin | -200.6% | 6.0% |
| Net margin | -189.8% | -3.8% |
| Return on equity | -36.1% | -3.8% |
| Free cash flow | $52.4m | $1.2m |
| Cash | $804,098 | $3.8m |
| Total debt | $1.8m | $9.1m |
| Debt to equity | 1.5% | 33.6% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 73 |
| Market value | $542,706 | $95.8m |
| Price vs our value range | — | Above our value range |
| Moat score | — | 34 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 8 buys, 0 sales |